疗效和不良反应分别用简明精神病评定量表（BPRS）和副反应量表（TESS）进行评定，并测定治疗第1，2，4，6周的稳态血药浓度。

Therapeutic efficacy was measured by BPRS and the adverse reaction was rated by TESS. Steady serum level was monitored within 1, 2, 4, 6 week.

youdao

以阳性和阴性症状量表（PANSS）评定临床疗效，以副反应量表（TESS）评定不良反应。

The efficacy was evaluated by positive and negative symptom scale(PANSS), and the side effects by treatment emergent symptom scale(TESS).

youdao

采用异常不自主运动量表（AIMS）和简明精神病评定量表（BPRS）及副反应量表（TESS）在治疗前及治疗后1、2、4、6周末分别评定疗效及不良反应。

The efficacy and safety were assessed with AIMS, BPRS and TESS at the end of week 1,2,4 and 6.

youdao